Condition: Verruca Vulgaris · Warts · Common Wart · Sponsor: Veradermics, Inc.
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Site 07 | Fort Smith, Arkansas, United States | — |
| Site 16 | San Diego, California, United States | — |
| Site 02 | Plainfield, Indiana, United States | — |
| Site 13 | Louisville, Kentucky, United States | — |
| Site 15 | Baton Rouge, Louisiana, United States | — |
| Site 09 | New Brighton, Minnesota, United States | — |
| Site 01 | Anderson, South Carolina, United States | — |
| Site 06 | Greenville, South Carolina, United States | — |
| Site 11 | Knoxville, Tennessee, United States | — |
| Site 03 | Arlington, Texas, United States | — |
| Site 04 | Austin, Texas, United States | — |
| Site 10 | College Station, Texas, United States | — |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05799157